Dear Americans, On August 1, 2023, I wrote to you with FDA Commissioner Robert Califf to address the lack of availability of certain prescription stimulant medications. As we said then, the U.S. Food and Drug Administration (FDA)and the Drug Enforcement Administration (DEA) recognize the important role that prescription stimulants play...

INTREPID confirms both liquid veterinary preparations and powdered xylazine are being used to adulterate fentanyl. INTREPID observed chemical markers in xylazine seizures that can assist in determining precursors, synthetic routes, and potentially connecting cases.

DEA received more than 38,000 comments on its proposed telemedicine rules and recently held two days of public listening sessions related to those rules. We continue to carefully consider the input received and are working to promulgate a final set of telemedicine regulations by the fall of 2024, giving patients...

“Fentanyl is the deadliest drug threat our nation has ever faced. These eight cases are the result of DEA’s efforts to attack the fentanyl supply chain where it starts — in China. Chinese chemical companies are fueling the fentanyl crisis in the United States by sending fentanyl precursors, fentanyl analogues...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of February 1 , 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in...

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is January 25, 2023 to November 5, 2023 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 2, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 15, 2022 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 1, 2022 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

On August 1, 2023, the Drug Enforcement Administration (DEA) and U.S. Food and Drug Administration (FDA) issued a joint letter updating the public on the ongoing prescription stimulant shortages impacting patients across the United States and actions to resolve these shortages. The DEA and FDA are committed to working together...